Related Experiment Videos
Combining tricyclic and monoamine oxidase inhibitor antidepressants
Abstract:
The charts of 150 inpatients and 51 outpatients treated with a monoamine oxidase inhibitor (MAOI)-tricyclic antidepressant combination were reviewed. The incidence and severity of side effects among the patients on the combined regimen were essentially the same as those seen in the control groups. There were no deaths or strokes resulting from use of this regimen. The most frequent troublesome side effect was orthostatic hypotension. We conclude that the use of a MAOI-tricyclic combination in oral therapeutic doses is safe. However, the efficacy of this combination has not yet been proved, and it may be particularly toxic if taken in an overdose.
Insights
Combining monoamine oxidase inhibitors (MAOIs) with tricyclic antidepressants appears safe for patients, with similar side effect rates to control groups. However, efficacy requires further proof, and overdose toxicity is a concern.
Area of Science:
- Psychiatry
- Clinical Pharmacology
Background:
- Monoamine oxidase inhibitors (MAOIs) and tricyclic antidepressants (TCAs) are established antidepressant classes.
- Combined use of MAOIs and TCAs has been explored for enhanced efficacy.
- Concerns exist regarding the safety profile of combined antidepressant regimens.
Purpose of the Study:
- To evaluate the safety and tolerability of a combined MAOI-tricyclic antidepressant regimen.
- To assess the incidence and severity of side effects in patients receiving the combination therapy.
Main Methods:
- Retrospective chart review of 150 inpatients and 51 outpatients.
- Analysis of side effect profiles in patients on the combined regimen versus control groups.
- Documentation of adverse events, including deaths and strokes.
Main Results:
- The incidence and severity of side effects were comparable to control groups.
- No deaths or strokes were reported in patients using the MAOI-tricyclic combination.
- Orthostatic hypotension was the most frequent troublesome side effect.
Conclusions:
- Oral therapeutic doses of MAOI-tricyclic antidepressant combinations are deemed safe.
- The efficacy of this combined regimen requires further investigation.
- Potential for significant toxicity exists in cases of overdose.